ABIVAX enters into a manufacturing agreement with PCAS for ABX464, thus ensuring drug candidate supply for upcoming clinical trials

Paris, April 25th, 2016 - ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that it has signed a contract with PCAS Group, a global industrial manufacturer of pharmaceutical active ingredients, for the production and supply of ABX464, ABIVAX’s drug candidate for the treatment of HIV. 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41